The Cancer Cell Line Encyclopedia 1 (CCLE) and Cancer Genome Project 2 (CGP) are two independent large-scale efforts to characterize genomes, mRNA expression, and anti-cancer drug dose-responses across cell lines, providing a public resource relating cellular biochemical context to drug sensitivity. A recent study 3 analysed correlations between reported dose-response metrics and found inconsistency between CCLE and CGP, thus questioning the validity of not only these, but also other current and future costly large-scale studies. Here, we examine two metrics of drug responsiveness (slope and area under the curve) that we derive from the original CCLE and CGP data, and find reasonable and statistically significant consistency. Our results revive confidence that the CCLE and CGP drug dose-response data are of sufficient quality for meaningful analyses. There is a Reply to this Comment by Safikhani, Z. values from all sensitive cell line/drug pairs (same as in Fig. 1e ) stratified by drug, for drugs having at least 5 points. All correlation coefficients are Pearson.
metrics of drug responsiveness (slope and area under the curve) that we derive from the original CCLE and CGP data, and find reasonable and statistically significant consistency. Our results revive confidence that the CCLE and CGP drug dose-response data are of sufficient quality for meaningful analyses. There is a Reply to this Comment by Safikhani values from all sensitive cell line/drug pairs (same as in Fig. 1e ) stratified by drug, for drugs having at least 5 points. All correlation coefficients are Pearson. CCLE and CGP dose-responses, we calculated a common viability metric (0-100%) across a shared log 10 -dose range, and computed slope (m s ) and area under the curve (AUC s ) values (in which subscript 's' denotes the shared dose range) (Fig. 1a ). This analysis revealed surprisingly good quantitative agreement between the two studies (m s : population Pearson correlation coefficient (ρ) = 0.52, P < 10
; AUC s : ρ = 0.61, P < 10 −16 ). Furthermore, since a small m s or large AUC s value indicates insensitivity, these data suggest that most cell lines are insensitive to the majority of tested drugs (~ 85%, Fig. 1a, b) . Characterizing such insensitive trends with a sigmoid model meant for sensitive cell lines (that is, half-maximum inhibitory concentration, IC 50 ) may lead to incorrect dataset consistency conclusions.
To evaluate consistency of sensitivity classification between the two studies, we first asked eight people to curate binary sensitivity manually (all dose-response curves and their manually curated classification results are provided in the Supplementary Information). For manual curation, only data from a single database within the shared dose range was presented on each plot, and the order of plot presentation was randomized with respect to the study, the drug, and the cell line for each curator (see Extended Data Figs 1 and 2). Using the manual curation results, we built a separate support vector machine (SVM) classifier for each study with m s and AUC s as predictors (Fig. 1b) . Both SVMs performed well (Fig. 1c , middle two plots), and the decision boundaries are independently similar for CCLE and CGP (Fig. 1b, black dashed  line) . These SVM classifiers also seem to parse data derived from the full (not shared) range of drug doses effectively ( Fig. 1b; insets; m and AUC without subscript s), which may be important for future, database-specific analyses.
The manual curation data along with the SVM classifiers allowed evaluation of consistency between CCLE and CGP in terms of binary sensitivity classification (Fig. 1c) . Comparison of manual curation results shows high (~ 88%) and statistically significant consistency between the two studies overall (Cohen's kappa (κ) = 0.53 ± 0.025), and for most individual drugs (Fig. 1c, far left) . Using the CCLE SVM to classify CGP data, and vice versa (Fig. 1c, far right) , also yielded high and statistically significant consistency (88%, κ = 0.55 ± 0.025). These results strongly suggest that drug dose-response data in the CCLE and CGP can be considered consistent when used to classify binary sensitivity.
The drugs 17-AAG, paclitaxel and TAE684 account for 48% of the inconsistent drug/cell line pairs. We hypothesized that most of these and other inconsistent drug/cell line pairs would be located near the SVM decision boundary. The primary reason is because this boundary necessarily travels through the region of AUC s -m s space where determining binary sensitivity is the most challenging for manual curators (Fig. 1b , cyan to yellow dots denote uncertainty among curators). If true, then this would imply that a main factor driving the observed inconsistency is self-induced: imposing a strict cutoff. Indeed, most such inconsistent points are located close to the decision boundary; for CCLE 53% of the inconsistent points are within 0.1 distance units from the decision boundary, and 51% for CGP (Fig. 1d) . Manual inspection of these inconsistent binary classification cases also supports this interpretation (Supplementary Data 1) . We do observe some strongly inconsistent drug cell/line pairs (for example, Fig. 1a inset-middle, and Supplementary Data 1), but these are relatively rare, and are highly likely to be located far from a decision boundary. These results suggest that inconsistency between the two studies on the level of binary classification is, to a large extent, a result of the information loss associated with collapsing a two-dimensional continuous description of drug sensitivity onto a single binary variable. Thus, we propose that drug sensitivity is better described as a spectrum (AUC and m) than as a binary classification.
We next re-calculated and compared IC 50 data only from drug/ cell line pairs determined to be sensitive in either CCLE or CGP by the SVM classifier (another requirement was the existence of a nonextrapolated IC 50 value). We found good correlation between the two studies overall (Fig. 1e ; ρ = 0.69, P < 0.0001). However, stratification by drug generally yields poor IC 50 correlations (Fig. 1f) . Thus, caution should be taken for inference of IC 50 values for specific cell line/drug combinations from CCLE and CGP, despite consistency on the level of slope, area under the curve, and binary sensitivity classification. HaibeKains et al. 3 stratified IC 50 by drug for sensitive and insensitive lines (IC 50 values for insensitive lines are unreliable), which contributed to their conclusion of inconsistency.
We conclude that the drug dose-response data in CCLE and CGP are acceptably consistent for most cases. Furthermore, we made no attempts to remove potentially suspect dose-response data, but doing so in future efforts could further facilitate data usability. That the two studies are this consistent is quite remarkable, given the different viability assays used, as well as inescapable confounding factors such as cell confluency, clonal variations, genomic drift, different drug suppliers/batches, laboratories/equipment and serum composition. This suggests that the measured genomic and gene expression parameters may provide a robust cellular context that dictates drug sensitivity.
Methods
For each drug/cell line pair found in both CCLE and CGP, we calculated the slope and AUC of each dose-response curve (percentage cell viability versus log 10 drug dose) only in the shared dose range. These values were normalized to account for different dose ranges used by each drug. One CCLE point and one CGP point defined boundaries of the shared dose range to maximize data coverage. IC 50 values were calculated as the drug concentration needed to reach 50% cell viability (using a fit to a sigmoid response model) if within the shared dose range (see Supplementary Methods). All scripts and data needed to reproduce the figures, including the MATLAB code, are provided in Supplementary Data 2. In the accompanying Comment 1 , the authors make two main claims: (1) that viability metrics computed over the drug concentration range shared between datasets yield higher consistency than the same metrics computed over the full, often only partially overlapping, drug concentration range; and (2) that binary drug sensitivity classification (insensitive versus sensitive) as determined by manual curators increases the consistency of pharmacological profiles between the Cancer Genome Project (CGP) 2 and Cancer Cell Line Encyclopedia (CCLE) 3 . We appreciate the innovative approach followed by the authors, and our reanalysis confirms the marginal, but statistically significant, increase in consistency achieved through the use of viability metrics computed across a reduced but common range. However, our results indicate that manual classification of drug dose-response curves does not significantly increase the agreement between drug sensitivity calls compared to computational approaches. Notably, it is unclear whether the authors' manual approach will improve reproducibility of the biomarker discovery process, as collapsing of complex curves into discrete categories may result in a substantial information loss. Here we provide specific responses to the main results reported by Bouhaddou et al. 1 Similar to Pozdeyev et al. 4 and the Comment by Mpindi et al.
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, the authors investigated whether sensitivity metrics computed from the drug concentration range shared between CGP and CCLE yield higher consistency 1 . Using the authors' code 1 , we were able to implement their slope (m s ) and area under the curve (AUC s ) metrics (in which subscript 's' denotes shared dose range) in our PharmacoGx platform 6 with a minor improvement of the m s metric to prevent highly sensitive cell lines with flat drug dose-response curves to be classified as insensitive (see Supplementary Methods). We compared the AUC and m metrics computed from the full and shared drug concentration range for the pooled set of drug sensitivities. Our implementation of the drug doseresponse curve fitting and sensitivity computation further improved the authors' results: initial correlation for m s (ρ = 0.52) and AUC s (ρ = 0.61) both increased to 0.67. We then tested whether the common viability metrics constituted significant improvement over computations on the full drug concentration range. We observed a small but statistically significant improvement for both the m s and AUC s metrics (test of difference in correlations, P < 0.01; Supplementary Fig. 1 ). Stratifying our analysis per drug, we observed that the improvement in consistency, although significant, was marginal, with the exception of nilotinib (Supplementary Fig. 2 ). However, most of the drugs still yielded poor consistency (ρ < 0.5), which is in line with both our initial report 7 and our more recent reanalysis 8 . The authors investigated discretization of their continuous metrics to test whether binary classification would yield higher consistency, as estimated by the overall percentage agreement in drug sensitivity calls. However, such a statistic does not take into account the agreement that would be expected purely by chance owing to the large proportion of cell lines being insensitive to the tested drugs. The Matthews correlation coefficient (MCC) 9 addresses this issue. It is a balanced measure that can be used when the classes are of different sizes, and its significance can be computed using the χ 2 statistic for binary classes (Supplementary Methods). We illustrate the case of four drugs with different patterns of consistency in Supplementary Fig. 3 . Although all four drugs yield an overall agreement of greater than 92%, they exhibit a wide range of MCC values. Nilotinib is a good example of a consistent drug phenotype across cell lines (MCC = 0.86; Supplementary Fig. 3a ). PLX4720 yields moderate consistency (MCC = 0.68; Supplementary  Fig. 3b ). AZD0530 and erlotinib show only poor consistency (MCC = 0.42 and − 0.05, respectively; Supplementary Fig. 3c, d) . These examples support MCC as an appropriate statistic to discriminate between highly consistent drug sensitivity calls and those with poor concordance. We therefore used the MCC to compare different classification schemes, including those proposed by the authors.
Recognizing the difficulty of summarizing drug dose-response curves computationally, Bouhaddou et al. 1 used an unconventional approach to increase the consistency of drug sensitivity calls: they gathered a team of eight curators and asked them to classify each drug dose-response curve as either sensitive or insensitive. The authors report a Cohen's kappa (κ) calue of 0.53, which is in line with our estimated MCC value of 0.53 ( Supplementary Fig. 4 ). The authors qualified their manual classification as a high and statistically significant consistency. We disagree with the authors' claim 1 that their results provide evidence for high consistency. We refer them to the standards for strength of agreement for κ defined previously 10 , which would only classify observed consistency as moderate. More importantly, when classifications are stratified by drug, we do not observe a significant improvement of manual curation over the computational classifications based on AUC s and m s values (P > 0.12, Wilcoxon signed rank test; Supplementary Fig. 5 ). Consistent with our previous report, 10 out of 15 drugs (66.7%) yielded poor consistency (MCC < 0.5).
By pooling drug sensitivity data across drugs, the authors noticed a good quantitative agreement between the two studies, with estimated Pearson correlation coefficients (ρ) of 0.52 and 0.61 for AUC s and m s values, respectively 1 ; our improved implementation of their method increased the correlation to 0.67. Nevertheless, we disagree that this level of correlation constitutes evidence for good agreement, and define it as only moderate consistency based on the interpretation scale of our initial study 7 . More importantly, the common viability metrics only marginally improved consistency at the level of individual drugs (except for nilotinib), with most of the drug yielding inconsistent drug sensitivity values (ρ < 0.5; Supplementary Fig. 2 ). The authors made a similar observation 1 in their figure 1f, undermining their claim of drug response consistency in CGP and CCLE. Moreover, the main goal of CGP and CCLE consisted of finding new associations between molecular features and sensitivity to specific drugs 2, 3 . Since biomarkers are to be found for each drug separately, it is vital that pharmacological profiles are highly consistent at the level of individual drugs and not merely when averaged across a larger dataset.
In conclusion, our re-analysis of the new AUC s and m s metrics described by Bouhaddou et al. 1 showed that they represent a statistically significant improvement over the published drug sensitivity values, but the increase in consistency is only marginal for the vast majority of the drugs tested both in CCLE and CGP. Furthermore, manual classification of the drug dose-response curves does not appear to substantially improve the consistency of binary sensitivity calls over computational approaches and is not a scalable method. However, the authors 1 showed that manually classified drug dose-response curves could be used as a benchmark to train nonlinear computational predictors that could take into account the peculiar features of each individual dataset. Although there is no evidence that the authors' approaches 1 12) containing approximately 395,000 and 225,000 individual curves, respectively-will present major challenges, but the investment in these large pharmacogenomic warrants such efforts. Author A. C. Jin was a student in A.H.B. 's laboratory and left shortly after publication of the initial study, and did not participate in in the writing of this Reply. Authors Z.S., P.S. and M.F. developed the PharmacoGx software package, which enabled the analyses presented here; A.G. helped with the comparison of the different drug sensitivity metrics, and participated in the interpretation of the results and writing of this Reply.
